Last updated: June 23, 2026
Junel 1/20 is a combined oral contraceptive (COC) brand containing ethinyl estradiol (EE) 20 mcg and norethindrone acetate 1 mg in a 21/7 regimen. The supplier landscape depends on whether you mean the original brand product or specific generic/authorized generic (AG) versions sold under the same NDCs.
Who supplies JUNEL 1/20 (brand) and what’s the typical manufacturer role?
For branded Junel 1/20, the supply chain typically consists of:
- Market Authorization Holder / Labeler: owns the FDA NDA/labeling for the branded product.
- Primary drug product manufacturer: makes and packages tablets for finished dosage form distribution.
- Secondary packager (where used): handles packaging, labeling, or distribution logistics under contract.
Key decision point for procurement is the specific NDC you buy. Two products with the same “Junel 1/20” label term can differ in NDC, packaging site, or manufacturer depending on distributor, lot, and time period.
What generic versions of JUNEL 1/20 supply the US market?
JUNEL 1/20 has multiple AB-rated generics in the US market that supply the same therapeutic equivalence class: EE 20 mcg / norethindrone acetate 1 mg. Generic suppliers are defined at the level of:
- Drug product manufacturer (tablets and finished packaging)
- NDC labeler
- Lot-level manufacturing site
Procurement implication: switching suppliers is often driven by NDC substitution rules and sourcing availability, not by therapeutic differences.
Which companies are common suppliers for ethinyl estradiol / norethindrone acetate tablets?
Common generic tablet supply patterns for COCs include manufacturers that produce high-volume hormone tablet portfolios. In practice, supplier lists change by:
- NDC
- contract manufacturing arrangements
- FDA site-level manufacturing authorizations
- packaging format and distribution channel
Without an NDC-level reference, a reliable “top suppliers” list cannot be stated accurately without risking misidentification of the actual current manufacturers tied to specific NDCs and lot codes.
How do suppliers differ for specific NDCs of JUNEL 1/20?
Supplier identity for “Junel 1/20” procurement is NDC-specific:
- Same strength, different NDC can map to different manufacturing sites and labelers.
- Distributor vs labeler vs manufacturer can differ in public listings.
- Authorized generics may shift manufacturing footprints even if the label is branded.
A defensible supplier map requires the exact NDC(s) being sourced.
What Orange Book listings determine which manufacturers are supplying JUNEL 1/20?
Orange Book coverage is what drives regulatory traceability for:
- NDA-coded branded product
- AB-rated generic products
- patent-protected vs off-patent status (relevant for entry and supplier churn)
Orange Book also ties to the formal NDA/ANDA ecosystem, which is the authoritative anchor for identifying legal marketing entities and product listings.
How many suppliers typically compete for JUNEL 1/20 generics?
For high-volume COCs, the number of marketed generic competitors is typically more than one, often spanning multiple manufacturers and packagers. However, the precise count for “Junel 1/20” depends on:
- the current AB listings under the exact strength and dosage form
- any shortages and temporary market exits
- NDC granularity
Without NDC and Orange Book crosswalk, any numeric supplier count risks being inaccurate.
Which supply risks matter most for JUNEL 1/20 procurement?
For COCs, supply risk drivers are usually practical rather than technical:
- concentration of manufacturing at a small number of tablet-packaging sites
- seasonal demand fluctuations
- regulatory inspection outcomes at active manufacturing sites
- distributor allocation during shortages
Supplier diversification is the main mitigation strategy, but it requires NDC-level supplier mapping.
What manufacturing/IP barriers affect who can supply JUNEL 1/20?
In general terms, entrants for oral contraceptives must align with:
- NDA/ANDA regulatory pathways
- GMP manufacturing capability for tablet strength and imprint
- labeling compliance for the 21/7 regimen
For supplier decisions, the relevant barrier is less about “formulation difficulty” and more about the ability to maintain ongoing compliance at the approved site(s) for the exact NDC.
How does JUNEL 1/20 compare with other EE/norethindrone acetate strengths for supplier coverage?
Junel 1/20 is often compared operationally against other EE/norethindrone acetate COC strengths (e.g., different EE levels or norethindrone acetate mg amounts). Supplier overlap is common because:
- manufacturers run standardized tablet platforms
- packaging lines are shared across strengths
Still, supplier lists remain NDC-specific and can differ despite shared platform manufacturing.
Key Takeaways
- JUNEL 1/20 supplier identification is NDC-specific. Accurate supplier mapping requires the exact NDC(s) and the corresponding drug product listing entries.
- The market includes branded supply plus multiple AB-rated generic suppliers, typically with multiple manufacturing sites and packaging footprints.
- Procurement should anchor to Orange Book/ANDA listings and NDC traceability, because labeler and manufacturer can differ.
FAQs
-
How can I identify the current JUNEL 1/20 manufacturer for my lot/box?
Use the NDC on the specific carton and map it to the corresponding labeler and manufacturing site in the FDA listing records.
-
Are Junel 1/20 generics interchangeable at the NDC level?
Therapeutic equivalence is AB-rated strength/formulation level, but interchangeability in practice depends on NDC substitution rules and pharmacy/wholesaler stock.
-
Do shortages of ethinyl estradiol/norethindrone acetate affect multiple NDCs equally?
Shortages usually impact specific manufacturing and packaging sites, so effects can be uneven across NDCs.
-
What is the best way to diversify JUNEL 1/20 suppliers?
Diversify by NDC and manufacturer site, not just by “brand vs generic,” to reduce exposure to a single packaging/manufacturing footprint.
-
Does supplier choice affect stability, packaging, or labeling compliance?
It can, because packaging format and lot manufacturing site are NDC-dependent even when active ingredients and strengths match.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration. (Accessed via FDA Orange Book database).
